Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis



Rating:

Share or cite this content

Citations should be made in the following way:
T. Karampitsakos (Patras, Greece), N. Mogulkoc (Izmir, Turkey), M. Kreuter (Heidelberg, Germany), W. Wuyts (Leuven, Belgium), S. Tomassetti (Florence, Italy), E. Bendstrup (Aarhus, Denmark), M. Molina-Molina (Barcelona, Spain), P. Spagnolo (Padova, Italy), E. Manali (Athens, Greece), Ö. Unat (Izmir, Turkey), N. Kahn (Heidelberg, Germany), L. Kolilekas (Athens, Greece), E. Rosi (Florence, Italy), L. Gori (Florence, Italy), C. Ravaglia (Forlì, Italy), Z. Daniil (Larissa, Greece), T. Prior (Aarhus, Denmark), I. Papanikolaou (Corfu, Greece), S. Aso (Barcelona, Spain), S. Tryfon (Thessaloniki, Greece), D. Papakosta (Thessaloniki, Greece), E. Balestro (Padova, Italy), S. Papiris (Athens, Greece), K. Antoniou (Heraklion, Greece), D. Bouros (Athens, Greece), A. Tzouvelekis (Patras, Greece). Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Europe.. 1205

Member's Comments

No comment yet.

Related content which might interest you: Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Prevalence of cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias Year: 2018 Treatment dilemmas in sarcoidosis - a retrospective cohort study Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013 Incidence and prevalence of Systemic Sclerosis-associated Interstitial Lung Disease in a multicenter prospective cohort study. Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting Source: International Congress 2014 – ILDs 6 Year: 2014 Pulmonary scar carcinomas: A two-year retrospective observational study Source: Annual Congress 2013 –Pathogenesis and risk of lung cancer Year: 2013 Is pulmonary sarcoidosis more severe in children? A multicentric retrospective study Source: International Congress 2014 – Sarcoidosis Year: 2014 Pirfenidone post-authorization safety registry (PASSPORT) – Interim analysis of IPF treatment Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Idiopathic Pulmonary Fibrosis based on disease behavior: Workshop summary of a Japanese multicenter study Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Clinical profile and early follow-up of patients receiving pirfenidone in the PIONEER observational study Source: International Congress 2014 – ILDs 6 Year: 2014 Long-term safety of pirfenidone in RECAP, an open-label extension study in patients with idiopathic pulmonary fibrosis, interim results Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Diagnosis of cardiac sarcoidosis: A crossectional study in 327 consecutive patients Source: International Congress 2014 – Sarcoidosis Year: 2014 Lung cancer in combined pulmonary fibrosis and emphysema: a large retrospective cohort analysis Source: ERJ Open Res, 6 (4) 00521-2020; 10.1183/23120541.00521-2020 Year: 2020 Nintedanib in Idiopathic Pulmonary Fibrosis: a single-centre real-life experience Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Real-life data on the safety and tolerability of Pirfenidone versus Nintedanib in Idiopathic Pulmonary Fibrosis (IPF) patients: A single-centre retrospective study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Value of community based Pulmonary Rehabilitation (PR) for patients with Interstitial Lung Disease (ILD): A retrospective review Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases Year: 2019 PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients Source: International Congress 2016 – IPF clinical Year: 2016 Treatment of IPF with inhaled IFN-gamma; planning for a clinical trial Source: International Congress 2014 – ILDs 3 Year: 2014 Idiopathic pulmonary fibrosis (IPF) patients in Poland – preliminary cohort analysis of EMPIRE registry Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 A Phase 2, double-blind, placebo-controlled study of N–acetylcysteine in combination with pirfenidone in patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 6 Year: 2014